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Taxane-Based chemotherapies result in serious physiological side effects in patients, including impaired muscle
metabolism, myocyte damage, impaired balance, pain, fatigue, and sensations of numbness in the extremities. As a
result, it has been suggested that individuals who have received taxane-based chemotherapies do not obtain the same
benefits from exercise as those who receive other forms of cancer treatment. PURPOSE: To determine if female
cancer patients who underwent taxane- based chemotherapies benefited from exercise as compared to those who
received non-taxane based treatments. METHODS: Retrospectively, 101 females (57.88 + 11.59), with female
cancers (Breast (79), Ovarian (10), Endometrial (4), Uterine (2), and Cervical (1)) enrolled in a cancer rehabilitation
program underwent a variety of fitness assessments, but only measures of VO2 are reported here. Each subject was
provided an individualized mixed home (2 days) and facility based (1 day) 12 week exercise intervention. RESULTS:
A strong positive correlation between VO21-VO22 (r=0.802, p=0.000), a low to moderate negative correlation between
VO21+age (r= - 0.365 p=0.000), a low negative correlation between VO22+age (r= - 0.215 p=0.036) were found. A
significant change from VO21 to VO22 (t=-5.372 p=0.000) was determined. While there were no differences between
Taxane and Non-Taxane measures of VO2, there was a trend in percent change in VO2 (F=3.306 p=0.073). There were
also no differences in any measure of VO2 between taxane and non-taxane treatments by cancer type. Regression
analysis indicated only age (t=2.775 p=0.007) predicted percent change in VO2 values and VO2 1 values (t=-3.606,
p=0.001), while age and cancer type predicted VO22 values (t=-2.117, p=0.037; t=-2.217, p=0.029 respectively).
CONCLUSION: The data does not support the hypothesis that taxane based chemotherapies result in lower VO 2
values, as both age and cancer type had greater overall effects on VO2. Additionally, significant improvements in VO2
after the 12-week exercise intervention, regardless of treatment type, age, or cancer type supports the effectiveness of
exercise-based cancer rehabilitation program to improve VO2 in a female cancer population.

